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2-oxoglutarate (2-OG or α-ketoglutarate) relates mitochondrial metabolism to cell function
by modulating the activity of 2-OG dependent dioxygenases involved in the hypoxia response
and DNA/histone modifications. However, metabolic pathways that regulate these oxygen
and 2-OG sensitive enzymes remain poorly understood. Here, using CRISPR Cas9 genome-
wide mutagenesis to screen for genetic determinants of 2-OG levels, we uncover a redox
sensitive mitochondrial lipoylation pathway, dependent on the mitochondrial hydrolase
ABHD11, that signals changes in mitochondrial 2-OG metabolism to 2-OG dependent diox-
ygenase function. ABHD11 loss or inhibition drives a rapid increase in 2-OG levels by
impairing lipoylation of the 2-OG dehydrogenase complex (OGDHc)—the rate limiting step
for mitochondrial 2-OG metabolism. Rather than facilitating lipoate conjugation, ABHD11
associates with the OGDHc and maintains catalytic activity of lipoyl domain by preventing
the formation of lipoyl adducts, highlighting ABHD11 as a regulator of functional lipoylation
and 2-OG metabolism.
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The ability to sense and respond to nutrient abundance is afundamental requirement for cell survival, and to achievethis, cells have evolved several strategies that link metabolic
function to transcriptional adaptation. One such strategy is the
coupling of 2-oxoglutarate (2-OG) metabolism to gene tran-
scription, whereby 2-OG, a key component of TCA cycle, can
facilitate cell function by modulating the activity of 2-OG
dependent dioxygenases involved in the hypoxia inducible factor
(HIF) response, DNA methylation, and histone modifications1.
The relevance of 2-OG in modulating the activity of these
dioxygenases is exemplified by changes in the relative abundance
of cellular 2-OG. An increased 2-OG/succinate ratio promotes
embryonic stem cell pluripotency2, and antagonises the growth of
solid organ tumours3 through increased hydroxymethylation of
DNA (5hmC) and histone demethylation. Conversely, elevated
cellular 2-OG can drive its own reduction to L-2-hydroxyglutarate
(L-2-HG), which counterintuitively inhibits 2-OG dependent
dioxygenases, leading to decreased DNA hydroxymethylation and
histone demethylation, activation of the HIF response, altered T
cell fate, and haematopoietic cell differentiation4–9. Consequently,
understanding how 2-OG metabolism is regulated has broad
biological implications.
Central to maintaining cellular 2-OG homeostasis is the 2-
oxoglutarate dehydrogenase complex (OGDHc, also known as the
α-ketoglutarate dehydrogenase complex), the rate-limiting
enzyme within the TCA cycle that oxidatively decarboxylates 2-
oxoglutarate to succinyl-CoA. This evolutionarily conserved
enzyme also requires lipoic acid, a redox sensitive cofactor that is
synthesised within the mitochondria and conjugated to a single
lysine within the OGDHc E2 subunit, dihydrolipoamide S-
succinyltransferase (DLST)10–12. The cyclical reduction and oxi-
dation of the two thiols of conjugated lipoic acid (lipoamide to
dihydrolipoamide) serves as a redox intermediate, coupling the
formation of succinyl CoA to generation of NADH. The impor-
tance of DLST and its lipoylation is highlighted by the recent
identification of genetic mutations leading to human disease.
Patients with germline mutations in lipoic acid synthesis genes
develop a severe variant of the neurological condition, Leigh
syndrome13, and loss of heterozygosity mutations in the OGDHc
lead to angiogenic tumours (pheochromocytomas and para-
gangliomas), similar to other hereditary cancer syndromes acti-
vating the HIF pathway14. However, how OGDHc function and
2-OG abundance is regulated is unclear.
Here, we use the sensitivity of the HIF pathway to 2-OG
abundance to gain insights into how 2-OG metabolism is con-
trolled. Using genome-wide CRISPR/Cas9 mutagenesis screens,
we identify an uncharacterised protein, αβ-hydrolase domain-
containing 11 (ABHD11), as a mitochondrial enzyme that
impairs OGDHc activity when depleted or inhibited. ABHD11
loss leads to the accumulation of 2-OG and formation of L-2-HG,
which inhibits 2-OG dependent dioxygenases involved in the HIF
response and DNA hydroxymethylation, similarly to genetic
disruption of the OGDHc. ABHD11 also associates with the
OGDHc and is required for catalytic activity and TCA cycle
function. However, ABHD11 does not alter the constituent levels
of the OGDHc. Instead, ABHD11 maintains functional lipoyla-
tion of the OGDHc, preserving the catalytic activity of DLST.
Together, these studies identify a key role for ABHD11 in 2-OG
metabolism, and demonstrate that lipoylation provides a pre-
viously unappreciated mechanism for mediating an adaptive
transcriptional response to changes in OGDHc function.
Results
ABHD11 mediates activity of 2-OG dependent dioxygenases.
To find genes involved in 2-OG metabolism we utilised the
sensitivity of the HIF response to 2-OG availability, and carried
out CRISPR/Cas9 mutagenesis screens in human cells using a
fluorescent HIF reporter we developed4,15. This reporter encodes
the consensus HIF responsive element (HRE) in triplicate that
drives the expression of GFP fused to the oxygen and 2-OG
sensitive region of HIF-1α (Supplementary Fig. 1a)4,15. Therefore,
reporter stability is dependent on 2-OG dependent dioxygenase
activity of the prolyl hydroxylases (PHDs or EGLNs)16,17, which
was confirmed with treatment with the PHD inhibitor dimethy-
loxalylglycine (DMOG), cell permeable 2-OG (dimethyl 2-OG) or
incubation in 1% oxygen (Supplementary Fig. 1b–d)4,7,15.
Two genome-wide CRISPR sgRNA libraries were used to
identify genes that when mutated activated the HIF reporter:
the Brunello human genome-wide library (containing
76,441 sgRNA)18, and the Toronto genome-wide knockout
library (containing 176,500 sgRNA)19. HeLa cells stably expres-
sing the HRE-GFPODD reporter and Cas9 were transduced with
each genome-wide library and iteratively sorted for GFPHIGH
cells by fluorescence-activated cell sorting (FACS) at day 10 and
day 18 (Fig. 1a). SgRNAs enriched by FACS were identified by
Illumina HiSeq and compared to a population of mutagenized
cells that had not undergone phenotypic selection (Fig. 1a, b)
(Supplementary Dataset 1). All screens were conducted in aerobic
conditions (21% oxygen), thereby preventing oxygen availability
limiting PHD function.
Both screens identified genes involved in the canonical
pathway for HIF stability (VHL, EGLN1 (PHD2)) and 2-OG
metabolism (OGDHc components, lipoic acid synthesis path-
way), validating the approach (Fig. 1b, c). Other biological
processes that were significantly enriched for sgRNA included
intracellular iron metabolism, the mTOR pathway, and transcrip-
tional regulation (Fig. 1b, c). The reliance of the HIF pathway on
these processes is well substantiated and in line with our prior
studies using gene-trap mutagenesis in haploid cells4,15. In
addition to these known pathways, we identified an unchar-
acterised α/β hydrolase, ABHD11, that was highly enriched for
sgRNA in both screens (Fig. 1b, c).
CRISPR/Cas9 mixed knockout populations of ABHD11 in HeLa
HRE-GFPODD cells, using three different sgRNA, validated the
findings from the screens (Fig. 1d, Supplementary Fig. 1e).
Stabilisation of HIF-1α was observed in multiple cell types (Fig. 1e,
f, Supplementary Fig. 1f) and complementation of ABHD11 mixed
knockout populations with overexpressed ABHD11 restored HIF-
1α levels (Fig. 1g), confirming that ABHD11 loss resulted in HIF-1α
accumulation.
We next asked if ABHD11 loss resulted in HIF-1α stabilisa-
tion through impaired 2-OG dependent dioxygenase activity.
PHD function can be readily assessed by measuring HIF-1α
prolyl hydroxylation using a HIF prolyl hydroxy-specific
antibody. Mixed knockout populations of ABHD11 stabilised
HIF-1α in a non-hydroxylated form, similar to the HIF-1α
stabilisation with DMOG (Supplementary Fig. 1g). In contrast,
inhibition of the VHL E3 ligase with VH29820, which stabilises
HIF-1α by preventing ubiquitination and proteasome-mediated
degradation showed high levels of hydroxylated HIF-1α
(Supplementary Fig. 1g). To verify that the decreased prolyl
hydroxylation was due to impaired PHD activity, we directly
measured prolyl hydroxylation of a recombinant HIF-1α protein
in control or ABHD11 deficient lysates4. Rapid prolyl hydro-
xylation was observed with a HeLa control lysate but this was
markedly reduced in the ABHD11 depleted cells, similarly to
loss of OGDHc function4 (Supplementary Fig. 1h, i). This PHD
inhibition activated a transcriptional HIF response, promoting
activation of HIF-1α target genes, VEGF and carbonic
anhydrase 9, similarly to loss of VHL or OGDH (Fig. 1h, i).
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We also explored whether ABHD11 loss altered the activity of
other 2-OG dependent dioxygenases involved in transcription.
ABHD11 KO cells showed a marked decrease in total DNA 5-
hydroxymethylcytosine (5hmC) levels, similar to those observed
when OGDHc function is impaired4 (Fig. 1j, Supplementary
Fig. 1j), indicating that Ten-eleven translocation (TET) activity
was impaired. However, the steady state levels of selected histone
marks were not altered by ABHD11 depletion (Supplementary
Fig. 1k). As levels of methylation depend on transferase activity,
demethylation and nucleosome turnover, lysine demethylases
(KDM) may still be affected by ABHD11 loss. Despite these
differences between TET and KDM activity, these studies
suggested that ABHD11 loss had broader implications for 2-OG
dependent dioxygenase function, aside from PHDs.
ABHD11 is required for OGDHc function. Impaired 2-OG
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that ABHD11 may be involved in 2-OG metabolism. Therefore, we
first examined the consequences of ABHD11 loss on 2-OG levels
and other TCA cycle intermediates. HeLa cells were depleted of
ABHD11 and small molecule metabolites traced by incubating cells
with uniformly 13C labelled ([U-13C5]) glutamine, followed by
liquid chromatography mass spectrometry (LC-MS) (Fig. 2a). Cells
deficient in OGDH were used as a control to measure perturbations
of 2-OG metabolism. ABHD11 depletion resulted in 2-OG accu-
mulation, similarly to OGDH loss (Fig. 2b). This increase in 2-OG
was not due to activation of the HIF response, as we previously
demonstrated that PHD2 deficiency does not perturb 2-OG levels4.
13C tracing confirmed that ABHD11 depletion impaired OGDHc
function, as TCA cycle metabolites downstream of the OGDHc
were decreased (succinate, fumarate and malate) (Fig. 2c–e), and
cells adapted by showing a shift from oxidative metabolism to
reductive carboxylation4,21, with a relative decrease inm+ 4 andm
+ 2 citrate, and an increase in m+ 5 and m+ 3 citrate iso-
topologues (Fig. 2f).
To substantiate that ABHD11 levels altered OGDHc function,
we measured OGDHc enzymatic activity in isolated mitochon-
dria, using a colorimetric assay which detects oxidation of
exogenous 2-OG with a redox sensitive probe (Fig. 2g). OGDHc
activity was decreased in ABHD11 deficient mitochondria,
similarly to levels observed with depletion of the OGDH subunit
(Fig. 2g). Loss of OGDHc function was not due to HIF
stabilisation, as VHL depletion had no effect on OGDHc activity
(Fig. 2g). Bioenergetic profiling also showed that ABHD11
depletion impaired oxygen consumption rates (Fig. 2h, i),
consistent with a major defect in the TCA cycle and oxidative
phosphorylation.
2-OG accumulation can impair 2-OG dependent dioxygenase
activity through the formation of L-2-HG (Fig. 2a)4,6,7,9.
Consistent with this, we observed an accumulation in 2-HG
levels following ABHD11 depletion, similarly to OGDH loss
(Fig. 2j). 2-HG predominantly accumulated in its L enantiomeric
form, although a small increase in D-2-HG was also observed
(Fig. 2k). Stable isotope tracing with [U-13C5]glutamine con-
firmed L-2-HG was derived directly from 2-OG in both the
ABHD11 and OGDH deficient cells (m+ 5 isotopologues)
(Fig. 2k).
Three enzymes are implicated in the formation of L-2-HG
from 2-OG: lactate dehydrogenase A (LDHA), malate dehydro-
genase 1 and malate dehydrogenase 26,8,9. Reductive carboxyla-
tion and an acidic environment potentiate the reduction of 2-OG
to L-2-HG and inhibition of LDHA alone is sufficient to prevent
L-2-HG formation4,7,8. Therefore, to confirm that L-2-HG was
responsible for decreased 2-OG dependent dioxygenase activity,
we treated cells with sodium oxamate, which inhibits LDHA as
well as decreasing 2-OG formation from glutamine4,7, or the
selective LDHA inhibitor GSK-2837808A, and measured HIF-1α
levels by immunoblot (Fig. 2l, m). Both treatments restored HIF-
1α turnover in ABHD11 deficient HeLa cells. Together, these
experiments confirmed that impaired OGDHc function and L-2-
HG accumulation was responsible for the decreased PHD activity
and activation of the HIF response.
ABHD11 is a mitochondrial hydrolase. ABHD11 is a member of
the alpha-beta hydrolase family, which contains 19 known genes,
and encodes an α/β hydrolase fold (Supplementary Fig. 2a),
typical of many proteases and lipases22. Unlike most alpha-beta
hydrolase family members, ABHD11 is predicted to localise to the
mitochondria through a classical mitochondrial targeting
sequence (Fig. 3a, Supplementary Fig. 2a). Therefore, we used
immunofluorescence microscopy to determine whether ABHD11
resided within mitochondria. Endogenous ABHD11 could not be
readily detected by immunofluorescence, but exogenously
expressed ABHD11 fused to GFP (ABHD11-GFP), which still
retained function (see Fig. 4f), colocalised with MitoTracker
DeepRed (Fig. 3b, c).
We biochemically confirmed ABHD11’s endogenous localisa-
tion using isolated mitochondria and a Proteinase K protection
assay. Cytoskeletal and outer membrane proteins were rapidly
lost with the addition of Proteinase K (30 min at 37 °C), but
ABHD11 levels were unaffected, suggesting localisation inside of
the outer membrane (Fig. 3d). Furthermore, ABHD11 was still
retained in mitoplasts, irrespective of proteinase K treatment,
consistent with its localisation to the mitochondrial matrix
(Fig. 3d).
As the stable isotope tracing demonstrated that ABHD11 loss
altered OGDHc activity, we determined if ABHD11 associated
with components of the complex. Both OGDH and DLST
immunoprecipitated with HA conjugated ABHD11 (Fig. 3e), and
ABHD11-GFP colocalised with the OGDH (Fig. 3f). We also
subjected immunoprecipitated ABHD11-HA to mass spectro-
metry, which confirmed the association with OGDH and DLST
(Supplementary Table 1). Furthermore, our findings were
consistent with a prior unbiased mass spectrometry analysis of
interactions between mitochondrial proteins, which identified
that ABHD11 associated with OGDH with high confidence23.
We next examined if ABHD11 enzymatic activity was required
for its effect on HIF-1α stability. Structural modelling of ABHD11
predicted a typical α/β hydrolase fold with two catalytic motifs
(Fig. 3a, g). Hydrolase activity is predicted to arise from the serine
nucleophile motif (GXSXG), but ABHD11 also encodes a putative
Fig. 1 Identification of ABHD11 as a mediator of 2-OG dependent dioxygenase activity. a HeLa HRE-GFPODD cells were transduced and mutagenised
with genome-wide sgRNA libraries (Brunello and Toronto KO). GFPHIGH cells were selected by iterative FACS and sgRNA identified by Illumina HiSeq.
b, c Comparative bubble plot (b) and table (c) of sgRNA enriched in the GFPHIGH cells between the two genome-wide sgRNA libraries compared to a
mutagenised population of HRE-GFPODD cells that had not been phenotypically selected. Genes enriched for sgRNA clustered into six main groups: (1) the
canonical HIF pathway, (2) OGDHc, Lipoylation (Lp) and 2-HG related pathways, (3) intracellular iron metabolism (iron, lysosomal), (4) mTOR, (5)
Transcription and (6) Uncharacterised. Unadjusted p value calculated using MaGECK robust rank aggregation (RRA); FDR= Benjamini-Hochberg false
discovery rate (multiple hypothesis adjustment of RRA p value). EGLN1= PHD2, EGLN3= PHD3. d–f HeLa HRE-GFPODD (d), MCF-7 (e) and Hep G2 (f)
cells stably expressing Cas9 were transduced with up to three different sgRNA targeting ABHD11. Reporter GFP or endogenous HIF-1α levels were
measured by flow cytometry (d) or immunoblot (e, f) respectively after 10-13 days. Endogenous ABHD11 levels were measured by immunoblot and β-actin
served as a loading control. g Reconstitution of mixed KO population of ABHD11 with exogenous ABHD11. HeLa cells expressing Cas9 were transduced
with sgRNA targeting ABHD11 as described. Targeted cells were also transduced with exogenous ABHD11 with the PAM site mutated. Cells depleted
of PHD2 served as a control for ABHD11 reconstitution. h–i Quantitative PCR (qPCR) of the HIF-1α target genes (VEGF and CAIX) in HeLa cells
following ABHD11 depletion by sgRNA (n= 3, SEM, *p < 0.028, **p < 0.0065, two-tailed one-sample t test of ratio). sgRNA targeting OGDH and VHL
were used as control for HIF-1α activation. j Genomic DNA was extracted from Hela control or mixed KO populations of ABHD11, LIAS or VHL, and
5hmC levels measured by immunoblot relative to total DNA content (Supplementary Fig. 1j). 5hmC levels were quantified using ImageJ. n= 3, Mean ± SEM
**p= 0.010; ns:p= 0.39, VHL compared to control; two-tailed t test (not adjusted for multiple comparison). Ct= control.
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acyltransferase motif (HXXXXD) found in several other α/β
hydrolases22 (Fig. 3a, g, Supplementary Fig. 2b). Reconstituting
ABHD11 deficient cells with the putative ABHD11 nucleophile
mutant (S141A) or acyltransferase mutant (H296A) did not
restore HIF-1α to basal levels, suggesting that ABHD11’s
hydrolase activity was required (Fig. 3h). Importantly, this was
not due to mis-localisation of the ABHD11 mutants, as both
ABHD11 S141A and ABHD11 H296A were visualised within
mitochondria (Supplementary Fig. 3a, b).
To confirm that these mutations were altering ABHD11
enzymatic activity, we purified wildtype and S141A ABHD11
and measured hydrolysis of p-nitrophenyl ester, a substrate
validated for generic α/β hydrolase activity22,24. Wildtype
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expression in HEK293T cells and FLAG tag affinity purification
(Supplementary Fig. 4). ABHD11 predominantly migrated as a
single species but a slower migrating form was apparent in the cell
extract and purified protein, consistent with an immature form
prior to mitochondrial insertion (Supplementary Fig. 4a). Mass
spectrometry analysis confirmed ABHD11’s identity and demon-
strated that the mitochondrial targeting sequence was lost in the
predominantly expressed form (Supplementary Fig. 4b) (the
slower migrating species was of too low abundance). Size
exclusion chromatography identified two peaks but full length
ABHD11 was only detected in the second peak, at an elution
volume consistent with a monomeric species (Supplementary
Fig. 4c, d). Hydrolysis of the p-nitrophenyl ester confirmed
ABHD11 enzymatic activity, but this was lost with the S141A
mutant and following heat treatment (Fig. 3i). Thus, ABHD11 is a
mitochondrial hydrolase that associates with the OGDHc, and
loss of its enzymatic activity leads to HIF-1α accumulation.
ABHD11 loss impairs lipoylation of the OGDHc. Conversion of
2-OG to succinyl-CoA by the OGDHc requires decarboxylation
and the formation of succinyl intermediate (succinyl-dihy-
drolipoate), dependent on the cyclical reduction and oxidation of
the lipoylated DLST subunit (Fig. 4a). Therefore, to understand
how ABHD11 is required for OGDHc function, we first examined
whether protein levels of core OGDHc components or its lipoy-
lation were altered. ABHD11 depletion did not alter total levels of
the OGDHc subunits (OGDH, DLST or DLD) in HeLa cells
(Fig. 4a, b). However, using a specific anti-lipoate antibody that
detects conjugated lipoamide, we observed a reproducible loss of
the faster migrating lipoylated protein species, attributed to the
lipoylated DLST subunit of the OGDHc (Fig. 4b, c). Immuno-
precipitation of endogenous DLST confirmed loss of lipoylation
following ABHD11 depletion, without altering total DLST levels
(Supplementary Fig. 5a), and this decreased DLST lipoylation was
observed in several cell types (Fig. 4d, e). Furthermore, in contrast
to complete disruption of lipoic acid synthesis by LIAS depletion,
ABHD11 loss preferentially decreased DLST lipoylation, without
altering the other abundantly lipoylated protein within the
mitochondria, the DLAT (dihydrolipoamide acetyltransferase)
subunit of the pyruvate dehydrogenase complex (PDHc)
(Fig. 4b–e, Supplementary Fig. 5b). Indeed, PDHc function, as
measured by [U-13C6] glucose stable isotope tracing, was not
impaired in the ABHD11 deficient HeLa cells (Supplementary
Fig. 6a–g), and lactate production was not increased compared to
control HeLa cells (Supplementary Fig. 6h).
Complementation studies were used to determine whether the
enzymatic activity of ABHD11 was required for lipoylation of the
OGDHc. Exogenous wildtype or mutant ABHD11 were expressed
in mixed ABHD11 KO populations and lipoylation levels
measured by immunoblot. DLST lipoylation was restored with
the wildtype ABHD11 but not with the S141A or H296A mutants
(Fig. 4f). HIF-1α levels were only reduced to basal levels by
reconstituting with wildtype ABHD11 but not the nucleophile
mutants (Fig. 4f), as previously shown.
Lastly, to confirm the enzymatic requirement of ABHD11 in
OGDHc lipoylation, we used a highly selective covalent inhibitor
of ABHD11, ML226, that was initially developed as a tool for
screening serine hydrolases25. ML226 treatment inhibited
ABHD11 p-nitrophenyl ester hydrolysis in vitro (Fig. 4g) and
decreased OGDHc lipoylation in HeLa cells (Fig. 4h) and
cultured myoblasts (C2C12) (Fig. 4i). In addition, DLST
lipoylation recovered after ML226 washout in cells, indicating
OGDHc lipoylation can be restored (Fig. 4j). Thus, ABHD11
hydrolase activity is required for OGDHc lipoylation.
ABHD11 maintains functional lipoylation of DLST. The find-
ing that ABHD11 loss showed a selective loss of DLST lipoylation
was unexpected, as prior genetic studies of lipoate conjugation
had not shown a requirement for an additional enzyme26. Fur-
thermore, we confirmed that ABHD11 loss differed to depletion
of other components of the lipoic acid synthesis pathway by
generating CRISPR/Cas9 mixed KO populations of the key
enzymes involved (Supplementary Fig. 7a, b). Lipoyl(octanoyl)
transferase 2 (LIPT2), LIAS, and lipoyltransferase 1 (LIPT1) all
reduced DLAT and DLST lipoylation in HeLa cells to a similar
level, but only ABHD11 showed a selective loss of DLST lipoy-
lation (Supplementary Fig. 7b). This preferential decrease in
DLST lipoylation following ABHD11 loss argued against a gen-
eral role for ABHD11 in lipoyl synthesis, and while it remained
possible that ABHD11 was required for the final catalysis of
DLST lipoylation, prior genetic studies suggested that LIPT1 was
sufficient for this step26–28.
Rather than acting as a conjugating enzyme, we hypothesized
that ABHD11 may directly or indirectly be involved in
maintaining a functional lipoate moiety on the OGDHc complex.
We observed that ABHD11 loss in HeLa cells led to decreased cell
viability after prolonged passage for three weeks. However, it was
unlikely that general growth inhibition was responsible for the
lipoylation phenotype as ML226 treatment, which efficiently
inhibited ABHD11, did not alter cell growth (Supplementary
Fig. 8a). We also examined whether ABHD11 activity altered the
mitochondrial redox environment, which could influence the
reduction and oxidation of lipoylated DLST. Stable isotope
tracing showed no overall change in cellular glutathione (GSH)
Fig. 2 ABHD11 is required for OGDHc function. a Schematic of the TCA cycle (oxidative metabolism) and reductive carboxylation (reductive metabolism),
illustrating the fate of 13C carbons upon incubation with [U-13C5]-glutamine. b–g Stable isotope tracing of control HeLa cells compared to mixed CRISPR
KO populations (sgRNA) of ABHD11 or OGDH incubated with [U-13C5] glutamine. 2-oxoglutarate (b), succinate (c), fumarate (d), malate (e) and citrate
(f), divided by metabolite isotopologues (m+ 0 to m+ 5) are indicated. Two biologically independent replicates, n= 5 technical replicates per sample,
mean ± SD (g) OGDHc activity in isolated mitochondria. Mitochondria were extracted from control or mixed CRISPR KO populations of ABHD11, OGDH or
VHL HeLa cells and OGDHc activity measured by a redox sensitive colorimetric probe for 2-OG oxidation. n= 3 biologically independent samples, mean ±
SEM, **p= 0.0082, two-tailed t test. h Bioenergetic assays of oxygen consumption rates (OCR) in control, ABHD11 deficient or OGDH deficient HeLa cells
(mixed KO populations). ABHD11 and OGDH were depleted as described, and analysed by using a Seahorse XFe24 Extracellular Flux Analyzer (n= 4
technical replicates per sample, mean ± SD). Three basal measurements were made at 9 min intervals followed by three measurements per treatment
(1 μM oligomycin, 1 μM FCCP and 1 μM antimycin/rotenone). OCR was normalised to total cell number. i Comparison technical repeats at first basal
measurement from (h); ***p= 6.3 × 10−5, two-tailed t test. j Measurement of 2-hydroxyglutarate (2-HG) levels following [U-13C5] glutamine stable
isotope tracing in control HeLa cells compared to mixed CRISPR KO populations (sgRNA) of ABHD11 or OGDH. Metabolite isotopologues (m+ 0 to m+ 5)
are indicated. Two biologically independent samples are shown; n= 5 technical replicates per sample, mean ± SD. k Relative quantification of 2-HG
enantiomers upon derivatisation with diacetyl-L-tartaric anhydride and LC-MS analysis. l, m Inhibition of lactate dehydrogenase A (LDHA) in ABHD11
deficient HeLa cells. Mixed CRISPR KO ABHD11, VHL or PHD2 cells were treated with sodium oxamate (Ox) (l) or GSK-2837808A (m) as indicated for
24 h. HIF-1α levels were measured by immunoblot.
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levels (Supplementary Fig. 8b). Small changes in mitochondrial
ROS were observed with ABHD11 loss, using MitoSOX Red,
similarly to OGDH or LIAS depletion (Supplementary Fig. 8c, d).
However, ML226 treatment, showed no change MitoSOX Red
levels, and importantly, Antimycin A, which increased mitochon-
drial ROS to higher levels than ABHD11 inhibition, was not
sufficient to activate the HIF reporter (Supplementary Fig. 8e).
Thus, alterations in mitochondrial ROS were unlikely to account
for the HIF stabilisation or altered lipoylation following ABHD11
loss or inactivation of the OGDHc.
To explore further how ABHD11 activity altered DLST
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moiety. Immunoprecipitated DLST was treated with a reducing
agent and then incubated with N-ethylmaleimide (NEM),
forming an NEM-lipoyl conjugate, which had previously been
shown to aid detection of the lipoate moiety29 (Fig. 5a,
Supplementary Fig. 9a). Interestingly, NEM treatment prevented
detection of immunoprecipitated lipoylated DLST by immuno-
blot (Supplementary Fig. 9a), demonstrating that the anti-lipoate
antibody only detected the functional lipoate and not the NEM-
modified form, suggesting that the apparent loss of DLST
lipoylation in ABHD11 deficient cells may be due to modification
of the lipoate moiety. We next measured levels of DLST
lipoylation (NEM-lipoyl) by label-free quantification on immu-
noprecipitated DLST from wildtype HeLa cells or those deficient
in LIAS or ABHD11 (Fig. 5a, b, Supplementary Fig. 9b).
To account for potential differences in DLST protein
abundance around the lipoylated region (DK*TSVQVPSPA),
we normalised these peptides to the sum of all DLST peptide
label-free quantification values. Approximately 50% of the
DK*TSVQVPSPA DLST peptide in wildtype cells was modified
with lipoate compared to the unmodified form and as expected,
nearly all the lipoate detected was modified with NEM (Fig. 5b).
DLST lipoylation was nearly completely lost in the LIAS deficient
cells, with the majority of the DLST lipoylated peptide region
found to be unmodified (Fig. 5b), confirming that this approach
could readily identify a defect in lipoyl synthesis and conjugation.
However, ABHD11 deficiency did not result in an accumulation
of the unmodified DK*TSVQVPSPA peptide, which could have
been expected with a defect in conjugation. Instead, both the
unconjugated or NEM-lipoyl DK*TSVQVPSPA peptide were
barely detectable, with a 10-fold decrease in abundance compared
to the control or LIAS null cells (Fig. 5b). This decrease was not
due to less total DLST, as DK*TSVQVPSPA levels were
normalised to other DLST peptides upstream or downstream of
the lipoylated region. Therefore, a modification of the
DK*TSVQVPSPA peptide of undefined mass accounted for the
apparent decrease in peptide abundance. Common post-
translational modifications (e.g., ubiquitination, phosphorylation
or acetylation), combinations of modifications, or known
DLST intermediates (e.g., succinyl-dihydrolipoamide, acyl-
dihydrolipoamide or S-glutathionylation) (Supplementary Data-
set 2) did not account for the peptide loss of the lipoylated DLST
region, suggesting the formation of lipoyl adducts that were not
detectable by mass spectrometry.
The thiols within the lipoamide moiety are sensitive to attack
by lipid peroxidation products, which disrupt OGDHc catalysis
by preventing the cyclical oxidation and reduction of the lipoyl
conjugate30,31 (Fig. 5c). We measured whether common lipid
peroxidation products formed in cells (4-hydroxy-2-nonenal (4-
HNE) or 4-oxononenal (4-ONE))30–32 modified the lipoate
moiety on immunoprecipitated DLST, but these modifications
did not account for the unassigned mass of the DLST peptide
(Supplementary Dataset 2). However, the complex nature of lipid
based adducts of undefined and variable lengths may preclude
their detection.
While the exact nature of the lipoyl adduct formed in ABHD11
deficient cells was unclear, we examined whether exogenous
treatment with 4-HNE could alter DLST lipoylation, similarly to
ABHD11 depletion. 4-HNE treatment of cell lysates preferentially
decreased detection of DLST lipoylation by immunoblot (Fig. 5d),
consistent with the formation of lipoyl adducts preventing
binding to the antibody. DLAT lipoylation was only affected at
high concentrations (5 mM) of 4-HNE (Fig. 5d), suggesting that
DLAT may be more resistant to lipoyl adduct formation than
DLST, and consistent with our findings that ABHD11 loss
preferentially effects the OGDHc.
Finally, to explore whether ABHD11 protected against to the
formation lipoyl adducts, such as those formed by 4-HNE, we
measured if ABHD11 loss or inhibition made the OGDHc more
susceptible to lipid peroxidation damage. Control or ABHD11
depleted HeLa cells or lysates were treated with 4-HNE, and
lipoylation detected by immunoblot. 4-HNE decreased the
detection of DLST preferentially to DLAT within cell lysates
(Fig. 5d), consistent with lipoyl adducts preventing detection of
the lipoyl moiety by immunoblot. 4-HNE treatment of cells also
decreased DLST functional lipoylation preferentially to DLAT,
and ABHD11 deficient cells were more susceptible to 4-HNE
treatment compared to the control cells (Fig. 5e). Overexpression
of ABHD11 inactive mutants competed with endogenous
ABHD11 to also show an increase lipoyl-adduct formation
following 4-HNE treatment (Supplementary Fig. 9c). ABHD11
overexpression did not increase DLST lipoylation compared to
control cells (Supplementary Fig. 9c) but this finding is consistent
with exogenous ABHD11 not increasing total lipoylation levels
and reflect that OGDHc lipoylation is tightly regulated, with only
50% of DLST modified by lipoylation. While these studies
demonstrated that 4-HNE could disrupt functional lipoylation,
we were concerned that the concentrations required were higher
than prior reports33,34, and considered that this may be due to the
presence of L-cysteine within media. Therefore, we repeated these
assays using lower concentrations of 4-HNE in media without L-
cysteine (Fig. 5f). We now observed impaired DLST lipoylation
with low concentrations of 4-HNE (40 µM) in control HeLa cells,
Fig. 3 ABHD11 is a serine hydrolase that associates with the OGDHc. a Schematic of ABHD11 with the putative mitochondrial targeting sequence (MTS),
mitochondrial processing peptidase (MPP) cleavage site and catalytic residues indicated (Serine 141, and Histidine 296). Modelled from UniProtKB—
Q8NFV4, and MitoFates prediction tool55. b Confocal micrograph of HeLa cells lentivirally transduced with ABHD11-GFP. Mitochondria were visualised
with MitoTracker Deep Red FM (MitoDeepRed); Scale = 10 μm, representative example from two biologically independent experiments and 14 images (c)
Pearson correlation coefficient (Pearson r) comparing colocalisation of GFP and MitoTracker in HeLa cells expressing ABHD11-GFP (n= 14). HeLa cells
expressing GFP under an SFFV promoter without a localisation signal served as a cytosolic control (pSFFV-GFP; n= 14) ***p= 7.0 × 10−6, two-tailed
Mann–Whitney U test. dMitochondrial protease protection assay. Mitochondria were extracted using the Qproteome Mitochondria Isolation Kit (Qiagen).
Proteinase K was added to the final concentrations indicated, and incubation at 37 °C for 30min. e Immunoprecipitation of ABHD11-HA with endogenous
OGDHc components. ABHD11-HA or the inactive mutants (S141A and H296A) were transduced into HeLa cells, lysed and immunoprecipitated using the
HA tag. TMEM199, a membrane bound protein tagged with HA (TM-HA) was used as a control. f Colocalisation of ABHD11 with the mitochondrial matrix
protein, OGDH. HeLa cells expressing ABHD11-GFP were fixed in paraformaldehyde. ABHD11 and OGDH subcellular localisation was visualised by
immunofluorescence confocal microscopy. Scale= 10 μm, representative image of five technical repeats. g In silico modelling of ABHD11 with putative
catalytic site and key residues S141 and H296 (Phyre2 structural prediction against a template of murine epoxide hydrolase, PDB: 1cr6, and visualised using
PyMOL 2.3). h Reconstitution of mixed KO population of ABHD11 with exogenous ABHD11, or enzymatic inactive mutants. i p-nitrophenyl esterase activity
of purified ABHD11-FLAG. Purified wildtype or S141A ABHD11-FLAG were incubated with p-nitrophenyl acetate and hydrolysis measured by rate of increase
in absorbance at 405 nm (37 °C for 40min). An empty FLAG vector (EV), that had undergone affinity purification, was used as a control. ABHD11
enzymatic activity was also measured following heat inactivation of the protein (90 °C for 5 min). n= 4, Mean ± SEM, ***p= 0.0006, two-tailed t test.
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with complete loss of DLST in ABHD11 deficient cells at 20 µM
4-HNE (Fig. 5f). Furthermore, while 4-HNE preferentially altered
DLST, DLAT lipoylation was also decreased in the ABHD11 null
cells compared to the controls (Fig. 5f). Similar findings were
observed with ABHD11 inhibition, consistent with a requirement
for ABHD11 to maintain functional lipoylation in the context of
lipid peroxidation products. In conclusion, while the nature of
adducts formed on lipoylated DLST remain to be fully
determined, these studies demonstrate that ABHD11 is required
for functional lipoylation of the OGDHc, and may protect against
the formation of lipoyl adducts, such as those formed by 4-HNE
(Fig. 6).
Discussion
This study identifies ABHD11 as a mitochondrial enzyme
required for OGDHc function, and to our knowledge, is the first
example of a mitochondrial pathway that maintains TCA cycle
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Moreover, we demonstrate that ABHD11 inhibition allows 2-OG
metabolism to be modulated in multiple cells and in a reversible
manner, with potential broad implications for altering cell fate-
decisions and manipulating 2-OG abundance in tumours.
The selective loss of lipoylated DLST following ABHD11
depletion initially suggested that it may be necessary for OGDHc
lipoate conjugation. However, a requirement for ABHD11 in
lipoate synthesis had not been previously observed13,26,35, and
LIPT1 deletion or human loss of function mutations prevent
PDHc and OGDHc lipoylation26–28. It was possible that ABHD11
transfers lipoate moieties between 2-oxoacid dehydrogenases, but
our mass spectrometry findings argued against this. If ABHD11
was required for lipoate transfer, the unmodified DLST peptide
should accumulate in ABHD11 depleted cells. Instead, we found
an absence of both the modified and unmodified lipoylated region
of DLST by mass spectrometry (Fig. 5b, c). Similar coverage of
DLST peptides upstream and downstream of the lipoylated region
confirmed that there was no change in total DLST levels following
ABHD11 loss. Therefore, a peptide of undefined mass must
account for the apparent loss of this region, indicating a post-
translational modification other than lipoylation or the formation
of a lipoyl adduct.
Common post-translational modifications (e.g. ubiquitination,
phosphorylation or acetylation), combinations of modifications,
or known DLST intermediates (e.g. succinyl-dihydrolipoamide,
acyl-dihydrolipoamide or S-glutathionylation) (Supplementary
Dataset 2) did not account for the peptide loss of the lipoylated
DLST region, suggesting that this DLST peptide was not uni-
formly modified. Lipid peroxidation products (hydroxyalkenals,
such as 4-HNE), arise from free radical propagation through
phospholipids31, and can easily react with thiol groups, inacti-
vating 2-oxoacid dehydrogenases by forming lipoyl adducts30.
We did not observe 4-HNE lipoyl adducts on immunoprecipi-
tated DLST, but the hydrophobicity and complex nature of these
adducts32 may preclude their detection by mass spectrometry,
accounting for the apparent loss of the DLST DK*TSVQVPSPA
peptide that we observed (Fig. 5b). We also required high con-
centrations of 4-HNE to decrease detectable lipoylation in
immunoprecipitated DLST, and 0.1 mM 4-HNE in cells incu-
bated in serum-free media. High levels or prolonged treatment of
4HNE may lead to depletion of cellular antioxidant levels and
apoptosis36,37, but we did not observe changes in DLAT lipoy-
lation at 0.1 mM consistent with a selective effect on DLST, as
previously observed38. Furthermore, treatment of HeLa cells with
4-HNE in media without L-cysteine resulted in selective loss of
DLST lipoylation at lower, biologically relevant 4-HNE
concentrations33,34.
The apparent specificity of ABHD11 for DLST may relate to
the preponderance of lipoyl adducts formed by the OGDHc
compared to other lipoylated proteins, or selectively binding to
the OGDHc, rather than all 2-oxoacid dehydrogenases. It is
possible that ABHD11 may regulate DLST indirectly, but this is
unlikely to be due to altered mitochondrial ROS (Supplementary
Fig. 8). The association with DLST and OGDH (Fig. 3e), and
marked accumulation of 2-OG (Fig. 2) are also consistent with a
direct role on OGDHc function. These findings are also sup-
ported by prior mass spectrometry interactome studies, showing
an association of ABHD11 with OGDH23. Whether ABHD11
interacts with other 2-oxoacid dehydrogenases will be of interest
to explore further. We observed that ABHD11 can interact with
DLAT by mass spectrometry (Supplementary Table 1), and a
small decrease in DLAT lipoylation following ABHD11 loss was
observed. ABHD11 deficient cells were also more susceptible to
impaired lipoylation following 4-HNE treatment. However,
ABHD11 loss did not increase pyruvate levels in HeLa cells
(Supplementary Fig. 5), which would be expected if PDHc activity
was significantly impaired.
ABHD11 is one of a family of alpha-beta hydrolase domain-
containing enzymes, which as a group are poorly characterised.
Of these, only ABHD10 and ABHD11 are known to be mito-
chondrial39. ABHD10 is has recently been shown to be an acyl
protein thioesterase, with S-depalmitoylase activity against the
anti-oxidant protein peroxiredoxin-540. These findings would be
consistent with our observations for ABHD11 regulating the
thiol-containing lipoate moiety on DLST. However, ABHD11 has
less sequence identity with ABHD10 than other ABHD family
members (Supplementary Fig. 2), and is not inhibited by
ML22625.
This work provides insights into the functional role of
ABHD11, for which no physiological substrate or role has been
identified previously. ABHD11 is one of ~26 genes included in
the 7q11.23 hemizygous deletion of Williams-Beuren syndrome, a
rare multisystem disorder often characterised by developmental
and cardiac abnormalities41. While the phenotype of cardiac and
soft tissue disease is felt largely due to loss of Tropoelastin 1
(ELN1)41, a functional understanding of ABHD11 may offer
some insights into aspects of this syndrome. It will also be of
interest to explore further the biological consequences of
ABHD11 loss compared to other lipoate enzymes. ABHD11 loss
disrupts the TCA cycle, impairing oxidative phosphorylation and
promoting reductive metabolism, but ABHD11 has a distinct
metabolic phenotype compared to loss of other lipoic acid
pathway enzymes. Germline mutations in LIAS, LIPT2 and
LIPT1 result in impaired PDHc and OGDHc activity13,27,42,43,
Fig. 4 ABHD11 loss impairs lipoylation of the OGDHc. a OGDHc compromises 3 subunits: OGDH (E1) catalyses the oxidation of 2-OG to form the
succinyl moiety, releasing carbon dioxide (CO2) and reducing the lipoate to form a succinyl-dihydrolipoate intermediate. DLST (E2) catalyses transfer of
the succinyl moiety to Coenzyme A (CoA), forming succinyl CoA and releasing dihydrolipoylated DLST. Dihydrolipoate is oxidised by DLD (E3) to
reform lipoate, with the free electrons reducing NAD+ to NADH. Thus 2-OG oxidation is coupled to cyclical lipoate reduction/oxidation and NADH
formation. b, c Immunoblot and quantification of OGDHc subunits and lipoylation in ABHD11 or LIAS deficient cells. HeLa cells were transduced with
sgRNA targeting ABHD11 or LIAS to generate mixed KO populations, and probed for OGDHc components (b). Lipoate (Lp) antibody detects lipoylated
proteins. The predominant lipoylated proteins, DLAT and DLST, are indicated. ImageJ quantification of lipoyl-DLST (left) and DLST (right), n= 5
biologically independent samples (c). Mean ± SEM, ***p= 0.0004, ns:p= 0.19, two-tailed one sample t test. Ct= control (d, e) Immunoblot OGDHc
subunits and lipoylation in ABHD11 or LIAS deficient THP-1 or MCF-7 cells. THP-1 (d) or MCF-7 (e) cells were transduced with sgRNA targeting ABHD11 or
LIAS to generate mixed KO populations, and probed for OGDHc components or lipoate. β-actin served as a loading control. f Reconstitution of mixed KO
population of ABHD11 with exogenous ABHD11-GFP, or enzymatic inactive mutants. g ML226 treatment in vitro. Purified wildtype ABHD11-FLAG was
incubated with p-nitrophenyl acetate and hydrolysis measured by rate of increase in absorbance at 405 nm (37 °C for 30min), with addition of ML226 at
the indicated concentration. Hydrolysis activity was subtracted from a background control without ABHD11-FLAG, and is normalised to the activity of
ABHD11-FLAG with vehicle control. ϕ= vehicle control; n= 3. h, i ML266 treatment in HeLa cells (h) and C2C12 myoblasts (i). Cells were treated for 24 h
with ML226 at the indicated concentrations and lipoylation measured by immunoblot. j HeLa cells were treated with 1μM ML226, or 0.075% DMSO as a
vehicle (veh) control. ML226 was washed out after 24 h and lipoylation recovery measured by immunoblot.
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but ABHD11 loss did not significantly alter DLAT lipoylation in
several cancer lines. PDHc activity is required for lipogenesis, by
providing acetyl-CoA, and LIPT1 mutations result in defective
lipid synthesis44. As ABHD11 acts predominantly on the
OGDHc, it is possible that the preserved activity of PDHc fuels
lipogenesis, and cell survival, and it will be important to deter-
mine whether ABHD11 activity, and the resulting HIF activation,
feeds back on lipid synthesis and the mitochondrial fatty acid
pathway.
This study and prior reports demonstrate that human muta-
tions in lipoylation enzymes increase 2-OG levels and promote L-
2-HG formation4,42. However, how L-2-HG inhibits 2-OG sen-
sitive enzymes when 2-OG is abundant remains to be fully
resolved. It is possible that L-2-HG may allosterically inhibit the
enzymes, or that additional factors aside from L-2-HG result in
decreased dioxygenase activity. The reasons for the propensity to
form L-2-HG under certain conditions of 2-OG accumulation
also remains to be determined, as in other cellular responses, such
as embryonic stem cell pluripotency2, 2-OG treatment does not
result in inhibition of 2-OG dependent dioxygenases. These dis-
crepancies may relate to the reductive environment that occurs
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Fig. 5 ABHD11 prevents the formation of lipoyl adducts by lipid peroxidation products. a, b Mass spectrometry analysis of DLST lipoylation. DLST was
immunoprecipitated from HeLa control, ABHD11 deficient or LIAS deficient cells, and treated with NEM to modify the free thiols and maintain the lipoyl
moiety in a reduced state. After SDS-PAGE, protein samples were digested with Asp-N protease and analysed by LC-MS/MS. b Normalised level of
lipoylated DLST peptide compared to DLST reference peptide. Relative levels of the unmodified, NEM-dihydrolipoamide, and lipoamide DLST peptide are
shown. n= 3, Mean ± SEM. c Schematic of normal cyclical reduction and oxidation of the lipoyl moiety on DLST (left). The reduced dihydrolipoamide can
react with lipid peroxidation products (e.g., 4-HNE) to form lipoyl adducts through the free thiols, which may also propagate (right). d–f Effect of 4-HNE
treatment on lipoylation. HeLa cells lysates were treated with 4-HNE at the indicated concentrations for 60min (50 °C) and immunoblotted for lipoylated
proteins or total DLST (d). Control or ABHD11 deficient HeLa cells were treated with 4-HNE in serum-free Optimem (e) or serum and L-cysteine free
DMEM (f) for 90min (37 °C), lysed and immunoblotted for lipoylation and total DLST. .
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ABHD11 loss), or the metabolic phenotype of the cell (e.g. reli-
ance on oxidative phosphorylation versus glycolysis).
Lipoic acid has been traditionally described as an essential
cofactor for 2-oxoacid dehydrogenases, but only 50% of DLST in
HeLa cells was observed to be lipoylated in resting cells (Fig. 5b),
and OGDHc lipoylation was rapidly stored after washout of
ML226, suggesting a reserve capacity to alter lipoate levels and
increase OGDHc activity (Fig. 4j). These findings show that
lipoylation is a dynamic modification that must be maintained,
which is further supported by recent observations that SIRT4 act
as a lipoamidase, altering PDHc function29, and that increased
lipoylation can enhance brown adipose tissue function, decreas-
ing age-associated obesity45. Therefore, modulating lipoylation
through ABHD11 activity provides an attractive approach to
manipulating 2-OG metabolism. Moreover, these studies extend
the role of lipoylation beyond an enzymatic cofactor, to a
dynamic modification that couples the mitochondria to a tran-
scriptional adaptive response mediated by 2-OG and oxygen
sensitive enzymes.
Methods
Cell lines and reagents. HeLa, MCF-7, C2C12 and HEK293T cells were main-
tained in DMEM (Sigma D6429), and THP-1 cells maintained in RPMI-1640
(Sigma R8758), both supplemented with 10% foetal calf serum (Sigma P4333)
and 100 units/ml penicillin with 100 µg/ml streptomycin, in a 5% CO2 incubator at
37 °C. HeLa HRE-GFPODD cells were produced by lentiviral transduction of the
HRE-GFPODD reporter4. All cell lines were authenticated (Eurofins). Hypoxia
treatments were performed at 1% oxygen, 5% CO2 in a H35 Hypoxystation (Don
Whitley Scientific).
Full details of reagents and antibodies used are shown in Supplementary
Table 2.
Constructs. CRISPR sgRNAs were cloned into a lentiviral sgRNA expression
vector pKLV-U6gRNA(BbsI)-PGKpuro2ABFP46. All sgRNA sequences are
detailed in Supplementary Table 3.
ABHD11 constructs were generated from the I.M.A.G.E. cDNA clone
(IRATp970F0688D, Source Bioscience), cloned into the pHRSIN pSFFV backbone
with pGK-blasticidin resistance (a gift from Paul Lehner), using NEBuilder HiFi
(NEB). Prior to assembly, silent mutations were introduced inside the sequence
targeted by ABHD11 sgRNA 2, using PCR primers detailed in Supplementary
Table 3. Mutations of catalytic residues serine 141 to alanine (S141A) and histidine
296 to alanine (H296A) of ABHD11 was created using NEBuilder HiFi, with
primers detailed in Supplementary Table 3. Lentiviral expression vectors (pHRSIN)
for ABHD11, S141A ABHD11 and H296A ABHD11 with C-terminal eGFP tags or
HA tags were created using NEBuilder HiFi (NEB). ABHD11 was also cloned into
a transfection vector, pCEFL 3xFLAG mCherry vector, encoding a C-terminal 3X
FLAG tag and mCherry under a separate promoter (a gift from David Ron)47,
using Gibson Assembly (NEB) and NEBuilder HiFi.
CRISPR/Cas9 sgRNA pooled libraries. The Human Brunello library was a gift
from David Root and John Doench18 (Addgene #73178). The Toronto human
knockout pooled library (TKO) Version 1 (Addgene ♯1000000069) was a gift from
Jason Moffat19.
Preparation of lentivirus and transductions. HEK293T cells were transfected
using TransIT-293 (Mirus) according to the manufacturer’s protocol. For small
scale experiments, lentivirus was produced in 6-well plates containing 2 ml media,
using 2 µg DNA (DNA was mixed in a 3:2:4 ratio of the relevant expression
plasmid, pCMV-dR8.91 (gag/pol) and pMD.G (VSVG)48. Viral supernatant was
harvested after 48 h, passed through a 0.45 µm filter, and frozen at −80 °C.
Cells were transduced with lentivirus by adding an appropriate volume of
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Fig. 6 ABHD11 regulation of OGDHc activity. Working model for functional lipoylation of the OGDHc. a Cyclical reduction and oxidation of lipoate is
required for OGDHc catalytic activity, and this process requires ABHD11 which associates with the OGDHc, maintaining functional lipoylation and allowing
the conversion of 2-OG to succinyl CoA. bWhen ABHD11 is depleted or inhibited, lipoyl adducts form, preventing functional lipoylation. These adducts may
arise from lipid peroxidation products (e.g. 4-HNE) formed by ROS generated by the OGDHc or by the electron transport chain, or by other as yet
undefined mechanisms. Loss of functional lipoylation leads to 2-OG accumulation and the formation of L-2-HG, which can inhibit 2-OG dependent
dioxygenases involved in the HIF response and DNA hydroxymethylation.
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250 µl of virus with 5 × 104 cells in a 24-well plate made up to 1 ml media. For the
screens, a titration of increasing volumes of virus was used, with 106 HeLa cells in a
6-well plate. Cell plates were centrifuged for 1 h at 37 °C at 750 × g immediately
after addition of virus.
Whole-genome CRISPR/Cas9 forward genetic screens. HeLa HRE-GFPODD
cells were transduced with Streptococcus pyogenes Cas9 (pHRSIN-FLAG-NLS-CAS9-
NLS-pGK-Hygro)49 and selected for Cas9 expression using hygromycin. 5 × 107
(Brunello) or 108 (TKO) HeLa HRE-GFPODD cells were transduced with the appro-
priate volume of pooled sgRNA virus (multiplicity of infection (MOI) of ~0.3),
maintaining at least 150-fold sgRNA coverage. After 30 h, cells were treated with
puromycin 1 µg/ml for 5 days. Representation was maintained throughout the screen
such that no selection event occurred where the library was cultured at fewer than 200
times the number of sgRNA sequences in the library. The library was pooled
immediately before any selection event.
FACS was performed by harvesting 108 cells, washing the cells in PBS, and then
resuspending them in PBS containing 2% foetal calf serum and 10mM HEPES (Sigma
H0887). Cells were sorted using an Influx cell sorter (BD); GFP-high cells were chosen
in a gate set at one log10 unit above the mode of the untreated population.
Genomic DNA was extracted using a Gentra Puregene Core kit (Qiagen).
Lentiviral sgRNA inserts were amplified in a two-step PCR (with Illumina adapters
added on the second PCR), as previously described49. For the TKO screen, the
forward inner PCR and sequencing primers were modified (Supplemental Table 3).
Sequencing analysis was performed by first extracting the raw sequencing reads,
trimming the first 20 bp (FASTX-toolkit), and aligning against the appropriate
sgRNA library using Bowtie50. Read counts for each sgRNA were compared
between conditions, and Benjamini-Hochberg false discovery rates for each gene
calculated, using MAGeCK51 (Supplementary Dataset 1). The analysis presented
compares DNA extracted following the second sort to an unsorted DNA library
taken at the same timepoint.
Flow cytometry. HeLa HRE-GPPODD cells were washed in PBS and fixed in PBS 1%
formaldehyde prior to analysis. For MitoSOX Red staining HeLa cells were plated in
24-well plates. After 24 h cells were treated with or without 10 μM Antimycin A for
37 °C for 30min, washed with PBS or Hank’s Balanced Salt Solution (HBSS), and
then stained with 5μM MitoSOX Red in PBS or HBSS for 10min at 37 °C. Cells were
harvested and resuspended in PBS for analysis by flow cytometry (BD Fortessa;
software: FACSDiva 8.0). Flow cytometry gating strategy is shown in Supplementary
Fig. 10. Images were presented using FlowJo v10 (BD).
Immunoblotting and immunoprecipitation. Cells were lysed in an SDS lysis
buffer containing 2% SDS, 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM dithiothreitol,
10% glycerol and 1:200 Benzonase nuclease (Sigma), for 15 min at room tem-
perature, then heated at 90 °C for 5 min. Proteins were separated with SDS-PAGE
electrophoresis, transferred to a PVDF membrane, and probed using appropriate
primary antibodies and a secondary with HRP conjugate. Densitometry mea-
surements were made using ImageJ52.
To identify protein interactions with ABHD11, HeLa cells lentivirally
transduced with ABHD11 with a C-terminal HA tag were lysed in a buffer
containing 100 mM Tris pH 8.0, 140 mM NaCl, 1% IGEPAL CA-630 (Sigma),
1 mM PMSF (Sigma P7626) and cOmplete Protease Inhibitor Cocktail (Roche).
After centrifugation at 17,000 × g, the supernatant was pre-cleared using Sepharose
CL-4B (GE Heathcare) and then incubated with EZView HA Red Anti-HA Affinity
Gel (Sigma E6779) overnight on a rotator. Resins were washed with Tris-buffered
saline containing 0.1% IGEPAL CA-630, and a further two washes with Tris-
buffered saline. Proteins were eluted using an SDS lysis buffer (4% SDS, 100 mM
Tris pH 7.4, 300 mM NaCl, 2 mM dithiothreitol, and 20% glycerol) heated at 90 °C
for 5 min, and separated using SDS-PAGE.
Confocal microscopy. Mitochondrial labelling was performed using MitoTracker
Deep Red FM (Thermo M22426). Cells were cultured overnight on a 1 cm glass
coverslip, incubated with 250 nM Mitotracker Deep Red FM for 40 min, and after
washing with PBS fixed with 4% paraformaldehyde for 20 min. Cells were mounted
to slides using ProLong Gold Antifade Mountant with DAPI (Thermo).
For immunofluorescence microscopy of OGDH, cells were cultured overnight
on a 1 cm glass coverslip. After washing with PBS, cells were fixed with 4%
paraformaldehyde, permeablised (0.3% Triton X-100, 3% bovine serum albumin)
and stained for OGDH (primary antibody at 1:100 dilution for 30 min, Alexa Fluor
secondary at 1:1000 (Thermo A21245)). Cells were mounted to slides using
ProLong Gold Antifade Mountant with DAPI. Slides were imaged using an
LSM880 confocal microscope (Zeiss). Pearson correlation coefficient was calculated
using Zen Blue 2.3 (Zeiss).
Quantitative PCR. Total RNA was extracted using the RNeasy Plus minikit
(Qiagen) and reverse transcribed using Super RT reverse transcriptase (HT Bio-
technology Ltd). PCR was performed on the ABI 7900HT Real-Time PCR system
(Applied Biosystems; software: Quantstudio 1.3) using SYBR Green Master mix
(Applied Biosystems). Reactions were performed with 125 ng of template cDNA.
Transcript levels of genes were normalised to GAPDH.
Measurements of 2-OG dependent dioxygenase activity. The in vitro HIF-1α
prolyl hydroxylation activity of HeLa cell lysates against a His-tagged protein
corresponding to residues 530–652 of human HIF-1α protein4,15 was performed by
incubating 10 μM HIF-1α530–652 with 50 μl HeLa cell extracts in 20 mM HEPES
(pH 7.5, 150 mM NaCl and 1 mM DTT) for 15 min at 37 °C. Reactions were
terminated by the addition of SDS loading buffer, and proteins visualised by SDS-
PAGE. Images were quantified using ImageJ, and are presented as the ratio of
densitometry of hydroxylated to total HIF-1αODD peptide at the 15 min timepoint,
normalised to PHD2.
For the 5hmC dot blot assay, genomic DNA was extracted from HeLa cells
using a Gentra Puregene kit (Qiagen), and dot blotting for 5hmC levels performed
by serial dilutions of denatured genomic DNA on Hybond NX membranes4.
Following UV crosslinking the membranes were blocked with 1% bovine serum
albumin and 5% milk powder prior to probing with a rabbit polyclonal antibody to
5hmC (Active Motif). Total DNA levels were evaluated by methylene blue staining,
and relative densitometry measured using ImageJ.
For the KDM panel, cells were lysed in SDS lysis buffer and probed for selected
H3 methylation marks.
Mitochondrial protease protection assay. Mitochondria from 107 HeLa cells
were extracted using a Qproteome Mitochondria Isolation Kit (Qiagen). After the
final wash with mitochondria storage buffer, mitochondria were divided into tubes,
pelleted by centrifugation at 6000 × g and resuspended in either 10 mM Tris-HCl
pH 8.0 with 250 mM sucrose (for whole mitochondria), or 10 mM Tris-HCl pH 8.0
(for mitoplasts), to a final protein concentration of 1 mg/ml. Proteinase K (Sigma
P2308) was added to a final concentration of 12 or 24 µg/ml, based on methods
previously described53. Following incubation at 37 °C for 30 min, the reaction was
quenched with 1 mM PMSF. Mitochondria or mitoplasts were then pelleted again
by centrifugation at 6000 × g, lysed in SDS buffer and analysed by immunoblot.
Purification of ABHD11 from HEK293T cells. HEK293T cells were transfected
with the pCEFL-ABHD11 -3XFLAG tag plasmid. In brief, cells were seeded in a 14
cm dish at 70% confluency and transfected using 270 μg polyethylenimine (Sigma)
with 22.5 µg DNA in 6 ml Opti-MEM. Cells were harvested after 48 h, and lysed in
TBS buffer (100 mM Tris-HCl pH 8.0, 140 mM NaCl) with 1% Triton X-100 and
cOmplete Protease Inhibitor Cocktail (Roche). After centrifugation at 17,000 × g,
the supernatant was pre-cleared using Sepharose CL-4B (GE Healthcare) and
incubated overnight with FLAG M2 antibody conjugated beads (Sigma). Following
five washes with TBS, ABHD11-FLAG was eluted using 100 mg/l 3xFLAG peptide
(Sigma F4799), filtered using a 0.22 µm PVDF filter and separated using a Superdex
75 10/300 column on an Äkta-Pure liquid chromatography system (software:
Unicorn 6.3). 500 µl fractions were collected and protein content visualised by SDS-
PAGE and Coomassie staining. Protein identity was confirmed by LC-MS/MS.
Liquid chromatography mass spectrometry. Samples were reduced, alkylated
and digested in-gel using either trypsin, GluC or AspN. The resulting peptides were
analysed by LC-MS/MS using an Orbitrap Fusion Lumos coupled to an Ultimate
3000 RSLC nano UHPLC equipped with a 100 µm ID × 2 cm Acclaim PepMap
Precolumn (Thermo Fisher Scientific) and a 75 µm ID × 50 cm, 2 µm particle
Acclaim PepMap RSLC analytical column. Loading solvent was 0.1% formic acid
with analytical solvents A: 0.1% formic acid and B: 80% acetonitrile+ 0.1% formic
acid. Samples were loaded at 5 µl/min loading solvent for 5 min before beginning
the analytical gradient. The analytical gradient was 3-40% B over 42 min rising to
95% B by 45 min followed by a 4 min wash at 95% B and equilibration at 3%
solvent B for 10 min. Columns were held at 40 °C. Data were acquired in a DDA
fashion with the following settings: MS1: 375-1500 Th, 120,000 resolution, 4 × 105
AGC target, 50 ms maximum injection time. MS2: Quadrupole isolation at an
isolation width of m/z 1.6, HCD fragmentation (NCE 30) with fragment ions
scanning in the Orbitrap from m/z 110, 5 × 104 AGC target, 100 ms maximum
injection time. Dynamic exclusion was set to +/−10 ppm for 60 s. MS2 frag-
mentation was trigged on precursors 5 × 104 counts and above.
Raw files were processed using PEAKS Studio (version 8.0, Bioinformatics
Solutions Inc.). Searches were performed with either trypsin, GluC or AspN against
a Homo sapiens database (UniProt reference proteome downloaded 26/01/18
containing 25,813 sequences) and an additional contaminant database (containing
246 common contaminants). Variable modifications at PEAKS DB stage included
oxidation (M) and carbamidomethylatation with 479 built in modifications
included at PEAKS PTM stage.
p-Nitrophenyl ester hydrolysis assay. Hydrolase activity of ABHD11-FLAG (or
a heat-inactivated control made by incubation at 90 °C for 5 min) was assayed by
incubation in an assay buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl,
0.01% bovine serum albumin, 1.4% methanol, and 500 µM p-nitrophenyl acetate
(Sigma N8130). 1.5 µg enzyme was added to 200 µl assay buffer, and the formation
of p-nitrophenol assayed using a Clariostar plate reader (BMG Labtech), recording
absorbance at 405 nm while incubating at 37 °C for 40 min. The rate of formation
of p-nitrophenol was calculated from the slope of the absorbance curve, subtracting
the slope of a blank containing only assay buffer and substrate, and calibrated
against a standard curve of p-nitrophenol (software: Microsoft Excel for Mac 16).
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OGDHc activity assay. OGDHc activity was measured in whole cell lysates using a
Biovision ketoglutarate dehydrogenase activity assay (Biovision K678), according to
the manufacturer’s protocol. HeLa cells were lysed by three freeze-thaw cycles
followed by passing 10 times through a 26-gauge needle. Activity was subtracted
from a background control containing cell lysate but no substrate.
Mitochondrial bioenergetics assay. Dynamic measurements of oxygen con-
sumption rate and extracellular acidification were recorded using a Seahorse XFe24
(Agilent; software: Wave 2.3). HeLa cells were seeded 24 h beforehand at 1.5 × 104
cells/well, and assayed using the manufacturer’s Mito Stress Test protocol.
Stable isotope tracing by LC-MS. HeLa cells were seeded in five replicates in 6-
well plates 27 h prior to metabolite extraction, with a sixth well per condition used
for cell count. Twenty-four hours prior to extraction, media was changed to either
DMEM without L-glutamine (Sigma D6546) supplemented with 10% FCS and 4
mM [U-13C5]L-glutamine (Cambridge Isotopes CLM-1822), or DMEM without
glucose (Gibco 11966-025) supplemented with 10% FCS, 1 mM sodium pyruvate
and 25 mM [U-13C6]D-glucose (Cambridge Isotopes CLM-1396). Two biological
replicates were undertaken, with independent lentiviral transductions of the same
cell line on different days. Metabolites were extracted on dry ice, after washing with
ice cold PBS, with 1 ml per 106 cells of extraction buffer, containing 50% methanol,
30% acetonitrile, 20% water and 100 ng/ml HEPES. To quantify the two enantio-
mers of hydroxyglutarate, a subset was derivatised using 50 mg/ml diacetyl-L-
tartaric anhydride in 20% acetic acid/80% acetonitrile4.
Immunoprecipitation and mass spectrometry detection of lipoylation. HeLa
cells were lysed on ice for 30 min in a HEPES buffer (150 mM NaCl, 50 mM
HEPES pH 7.0, 1% IGEPAL CA-630, 1 mM nicotinamide (Sigma), 5 mM tris(2-
carboxyethyl)phosphine hydrochloride (Sigma), 1X cOmplete Protease Inhibitor
Cocktail (Roche), and 1 mM PMSF). Lysates were centrifuged at 16,900 × g for 10
min. For LC-MS experiments, free thiols were blocked by addition of 10 mM N-
ethyl maleimide (Sigma) and incubated on a rotator at 4 °C for 1 h.
Lysates were immunoprecipitated by incubation with protein G beads (GE 17-
0168-01), firstly for 1 h to pre-clear, and then overnight with the DLST or DLAT
antibodies (Supplementary Table 2). Resins were washed four times with Tris-
buffered saline containing 0.1% IGEPAL CA-630, followed by three washes with
Tris-buffered saline. Protein was eluted using 2% SDS, 50 mM Tris pH 7.4, 150 mM
NaCl, 1 mM dithiothreitol and 10% glycerol, and incubated at 90 °C for 5 min. The
proteins were then separated using SDS PAGE (Thermo NP0335), and visualised
using SimplyBlue SafeStain (Invitrogen).
For mass spectrometry analysis, in-gel AspN digest and sample analysis were
performed as previously described. To identify possible modifications of DLST
K110, raw files were processed using PEAKS Studio (version 8.0, Bioinformatics
Solutions Inc.) with the following parameters: AspN digestion; Human database
(UniProt reference proteome downloaded 18 Dec 2018 containing 21,066 proteins)
with additional contaminant database (containing 246 common contaminants);
oxidation and carbamidomethylation as variable modifications at the PEAKS DB
stage. The data were processed twice, with different variable modifications searched
at the PEAKS PTM stage, either with 485 PEAKS built-in modifications listed in
Supplementary Dataset 2 (sheet A) and 34 custom modifications listed in
Supplementary Dataset 2 (sheet B).
XIC were obtained from Thermo Xcablibur Qual Browser (4.0.27.13). Mass
ranges were limited to 564.79–564.80m/z, 658.81–658.82m/z and 784.87–784.88
m/z for the unmodified, lipoylated and 2x NEM lipoylated peptides respectively.
Label-free quantitation values were obtained by processing raw files with
MaxQuant (version 1.6.6.0) with the following parameters: specific AspN digestion;
Human database (UniProt reference proteome downloaded 18 Dec 2018
containing 21066 proteins); oxidation, lipoylation, 2x NEM lipoylation, N terminal
acetylation as variable modifications; carbamidomethylation as a fixed
modification; label-free quantification enabled. Label-free quantification values
were normalised to the sum of DLST peptides label-free quantification values.
ABHD11 structural prediction. A structural model of ABHD11 was obtained
using the NCBI reference sequence for ABHD11 transcript variant 1
(NP_683710.1), modelled with Phyre2 against a template of murine epoxide
hydrolase (PDB: 1cr6)54 and visualised using PyMOL 2.3 (Schrödinger, LLC). The
mitochondrial targeting sequence was mapped with the MitoFates prediction
tool55. Phylogenetic analysis and multiple sequence alignment of ABHD family
members was performed with protein sequences obtained from Uniprot (canonical
transcript variant) and aligned using Clustal Omega (EBI)56.
Statistics and reproducibility. Statistical analysis of the screens was performed
using MAGeCK version 0.5.551, testing the sgRNA read counts obtained following
the second sort against sgRNA read counts obtained from unsorted cells lysed at
the same timepoint. Quantification and data analysis of other experiments are
expressed as mean ± SEM and P values were calculated using two-tailed Student’s t-
test for pairwise comparisons, unless otherwise stated, and were calculated using
Graphpad Prism version 8. Metabolomic samples were blinded and randomised
prior to their evaluation. Qualitative experiments were repeated independently to
confirm accuracy. Specifically, Figs. 1e, f, g; 3e, h; 4f, i, j; 5d, f; Supplementary
Figs. 1e, g, k, 5a, b; 9c were repeated twice with similar findings. Figs. 2l, m; 3d; 4d,
e, h; 5e; Supplementary Figs. 1f; 4a, d; 7b and 9a were performed independently at
least 3 times. Representative data are shown in the figures. Uncropped original
scans of all immunoblots are displayed in Supplementary Fig. 11.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
SgRNA read count tables from CRISPR/Cas9 genetic screens are shown in
Supplementary Dataset 1. The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE57 partner repository with the
dataset identifier PXD020128 and the results and analysis are also available in
Supplementary Dataset 2. LC-MS metabolic profiling has been deposited in
MetaboLights58 MTBLS1875. Source data are provided with this paper (Source Data
File). Source data are provided with this paper.
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